Skip to main content
EVMN $7.04 -2.76%
EVMN logo
EVMN · Evommune, Inc.
Track EVMN — free
$7.04 -0.20 (-2.76%) At close · Nov 20
Market Cap
$291.10M
Shares
41.35M
Volume · Nov 20 549.4K Avg daily vol (3M) 834K
All webcasts

Earnings call · FY2026 Q3

Evommune, Inc. (EVMN) Q3 2026 Earnings Call

Concluded Nov 5, 2026
Nov 5, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $0 -100% YoY
Diluted EPS -$0.85
Net income -$30.88M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 12, 2026
Evommune licensed EVO570 from Hinova for $30 million upfront and raised approximately $30 million through a private placement, reporting $262.3 million in cash, cash equivalents and investments and cash runway into 2H 2029.
10-Q report · filed Nov 12, 2026
Evommune discontinued EVO756 development in CSU and AD after Phase 2b trials missed endpoints, while migraine development continues. It reported $262.3 million in liquidity and expects funding into the second half of 2029.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document